Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

InvestingZone

Founders Jean Miller Richard Brockbank

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 1
Average round size
info
The average size of a deal this fund participated in
$8M
Portfolio companies 1
Rounds per year 0.12
Lead investments 1
Exits 1
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Biopharma
Summary

InvestingZone is the famous VC, which was founded in 2013. The company was established in Europe in United Kingdom. The leading representative office of defined VC is situated in the London.

The typical case for the fund is to invest in rounds with 1 participant. Despite the InvestingZone, startups are often financed by Development Bank of Wales, Acceleris Capital, The Welsh Government. In the next rounds fund is usually obtained by Seneca Partners, Maven Capital Partners, Development Bank of Wales.

The usual things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2017.

The fund was created by Jean Miller, Richard Brockbank.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ADC Biotechnology, ADC Biotechnology. The fund has exact preference in some founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Biopharma, Biotechnology.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of InvestingZone:
Typical Co-investors
InvestingZone is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after InvestingZone:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
BioImpact Japan, Yamanashi, Yamanashi Prefecture
Doggett Equipment Services Group Baton Rouge, Louisiana, United States
GlobalLink1 Capital -
Momeni Digital Ventures Germany, Hamburg, Hamburg
Nio Advisors -
Odyssey Ventures Online Holding Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Outlier Ventures Base Camp England, London, United Kingdom
Phillips Smith Specialty Group Dallas, Texas, United States
Shanshan Venture Capital China, Shanghai
Techstars Austin Accelerator Austin, Texas, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent InvestingZone?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 1
Average round size 8M
Rounds per year 0.12
Peak activity year 2017
Lead investments 1
Exits 1
Crunchbase icon

Content report

The following text will be sent to our editors: